Salivary TNF-α, FoxO-1, and SIRT-1 Levels in Periodontitis and Smoking (NCT07764549) | Clinical Trial Compass
CompletedNot Applicable
Salivary TNF-α, FoxO-1, and SIRT-1 Levels in Periodontitis and Smoking
Turkey (Türkiye)80 participantsStarted 2025-10-24
Plain-language summary
This study examines whether smoking and gum disease (periodontitis) are linked to changes in three biological markers found in saliva: TNF-α, FoxO-1, and SIRT-1. These markers are involved in inflammation and the body's response to stress.
Eighty adults took part in the study, divided into four groups: healthy non-smokers, non-smokers with Stage III periodontitis (an advanced form of gum disease), healthy smokers, and smokers with Stage III periodontitis. Each participant had a dental examination and provided a saliva sample, which was analyzed in the laboratory to measure the levels of these three markers.
The goal of the study is to better understand how smoking and gum disease together affect the body's inflammatory and stress-response pathways, which may help guide future approaches to prevention and treatment.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 18 years or older
* At least 16 permanent teeth, excluding third molars
* Not receiving orthodontic treatment
* No systemic condition known to affect periodontal health
Exclusion Criteria:
* Pregnant or breastfeeding
* Diabetes mellitus, rheumatoid arthritis, hypertension, or another systemic disease that could influence periodontal tissues
* Periodontal treatment within the previous six months
* Use of antibiotics or anti-inflammatory medications within the previous six months
* Any local or systemic condition that could affect salivary biomarker concentrations
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Salivary TNF-α Concentration
Timeframe: Measured at a single time point at study enrollment
2
Salivary FoxO-1 Concentration
Timeframe: Measured at a single time point at study enrollment
3
Salivary SIRT-1 Concentration
Timeframe: Measured at a single time point at study enrollment